# US 6,730,683 B2 · Compounds of heteroaryl substituted imidazole, their pharmaceutical compositions and uses

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 6,730,683 B2
- Document ID: US6730683B2
- Status: Granted
- Kind: B2
- Application number: 09/919,251
- Filed: 2002-06-10
- Published: 2002-12-26
- Granted: 2004-05-04
- Earliest claimed: 1997-12-19
- Assignees: SmithKline Beecham Corporation
- Inventors: Timothy Francis Gallagher; Jeffrey Charles Boehm; Jerry Leroy Adams
- Web page: https://patentgrep.com/patent/US6730683B2

## CPC

- C07D 401/14: containing three or more hetero rings
- A61P 19/00: Drugs for skeletal disorders
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/12: Antivirals
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D 403/04: directly linked by a ring-member-to-ring-member bond
- C07D 403/14: containing three or more hetero rings
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Novel 1,4,5-substituted imidazole compounds and compositions for use in therapy as cytokine inhibitors.

## Claims

### Claim 1

A compound which is:
1-Cyclohexyl-4-(4-fluorophenyl)-5-[(2-phenylamino)pyrimidin-4-yl]imidazole;
1-Cyclohexyl-4-(4-fluorophenyl)-5-[[2[N-(3-morpholino)propyl]amino]pyrimidin-4-yl]imidazole;
1-Cyclohexyl-4-(4-fluorophenyl)-5-[[2-[N-(2-imidazol-4-yl)ethyl]amino]pyrimidin-4-yl]imidazole;
1-Cyclohexyl-4-(4-fluorophenyl)-5-[[2-[N-(3-pyridyl)methyl]amino]pyrimidin-4-yl]imidazole;
1-Cyclohexyl-4-(4-fluorophenyl)-5-[[2-[N-(3,3-diphenyl)propyl]amino]pyrimidin-4-yl]imidazole;
(+/−)-1-Cyclohexyl-4-(4-fluorophenyl)-5-[[2-[N-(1-methyl-3-phenyl)propyl]amino]pyrimidin-4-yl]imidazole;
N-4-[[[4-(4-Fluorophenyl)]-5-[[2-[(3-trifluoromethyl)phenyl]amino]]pyrimidine-4-yl]imidazol-4-yl]piperdinyl-N′-[(3-trifluoromethyl)phenyl]urea;
N-[2-[4-(4-Fluorophenyl)-5-[[2-(3,4-dichlorobenzyl)pyrimidin-4-yl]-1 H-imidazol-1-yl]ethyl]-3,4-dimethoxybenzamide;
N-[2-[4-(4-Fluorophenyl)-5-[[2-(4-methoxybenzylamino)pyrimidin-4-yl]-1 H-imidazol-1-yl]ethyl]-ethoxyacetamide;
1-Isopropyl-4-(4-fluorophenyl)-5-[2-phenylamino-pyrimidin-4-yl]imidazole;
1-Cyclopentyl-4-(4-fluorophenyl)-5-[2-phenylamino-pyrimidin-4-yl]imidazole;
1-[(1-t-Butoxycarbonyl)-4-piperidinyl]-4-(4-fluorophenyl)-5-[2-(2-methyl-4-fluorophenyl)amino]pyrimidin-4-yl]imidazole;
1-(4-Piperidinyl)-4-(4-fluorophenyl)-5-[2-(2-methyl-4-fluorophenyl)-amino]pyrimidin-4-yl]imidazole;
1-(4-Piperidinyl)-4-(4-fluorophenyl)-5-[2-(2-methyl-5-fluorophenyl)amino]pyrimidin-4-yl]imidazole;
1-(4-Piperidinyl)-4-(4-fluorophenyl)-5-[2-(2,6-dimethylphenyl)amino]pyrimidin-4-yl]imidazole;
1-(4-Piperidinyl)-4-(4-fluorophenyl)-5-[2-(2-methylphenyl)amino]pyrimidin-4-yl]imidazole;
1-(4-Fluorophenyl)-4-(4-fluorophenyl)-5-[2-phenylamino-pyrimidin-4-yl]imidazole;
1-(4-Fluorophenyl)-4-(4-fluorophenyl)-5-[2-(4-fluorophenylamino)-pyrimidin-4-yl]imidazole;
1-(4-Fluorophenyl)-4-(4-fluorophenyl)-5-[2-(4-methylphenylamino)-pyrimidin-4-yl]imidazole;
1-(4-Fluorophenyl)-4-(4-fluorophenyl)-5-[2-(2-methylphenylamino)pyrimidin-4-yl]imidazole;
1-(4-Fluorophenyl)-4-(4-fluorophenyl)-5-[2-(2,6-dimethylphenylamino)pyrimidin-4-yl]imidazol;
1-(4-Fluorophenyl)-4-(4-fluorophenyl)-5-[2-(4-2-morpholinylphenylamino)-pyrimidin-4-yl]imidazole; or a pharmaceutically acceptable salt thereof.

### Claim 2 (depends on 1)

A pharmaceutical composition comprising a compound, or pharmaceutically acceptable salt thereof, according to claim 1, and a pharmaceutically acceptable carrier or diluent.

### Claim 3 (depends on 1)

A method of treating a CSBP/RK/p38 kinase mediated disease in a mammal in need thereof, which comprises administering to said mammal an effective amount of a compound according to claim 1.

### Claim 4 (depends on 3)

The method according to claim 3 wherein the CSBP/RK/p38 kinase mediated disease is selected from psoriatic arthritis, Reiter's syndrome, rheumatoid arthritis, gout, traumatic arthritis, rubella arthritis and acute synovitis, rheumatoid spondylitis, osteoarthritis, gouty arthritis, sepsis, septic shock, endotoxic shock, gram negative sepsis, toxic shock syndrome, Alzheimer's disease, stroke, neurotrauma, CNS injury, restinosis, reperfusion injury, asthma, adult respiratory distress syndrome, cerebral malaria, chronic pulmonary inflammatory disease, silicosis, pulmonary sarcososis, bone resorption disease, osteoporosis, restenosis, stroke, cardiac and renal reperfusion injury, chronic renal failure, congestive heart failure, angiogenic diseases, thrombosis, glomerularnephritis, diabetes, graft vs. host reaction, allograft rejection, inflammatory bowel disease, Crohn's disease, ulcerative colitis, multiple sclerosis, muscle degeneration, eczema, contact dermatitis, psoriasis, pyresis, sunburn, or conjunctivitis.

### Claim 5 (depends on 1)

A method of treating inflammation in a mammal in need thereof, which comprises administering to said mammal an effective amount of a compound according to claim 1.

### Claim 6 (depends on 1)

A method of treating osteoporosis in a mammal in need thereof, which comprises administering to said mammal an effective amount of a compound according to claim 1.

### Claim 7 (depends on 1)

A compound according to claim 1 which is:
1-(4-Piperidinyl)-4-(4-fluorophenyl)-5-[2-(2-methylphenyl)amino]pyrimidin-4-yl]imidazole;
1-(4-Piperidinyl)-4-(4-fluorophenyl)-5-[2-(2,6-dimethylphenyl)amino]pyrimidin-4-yl]imidazole; or
1-(4-Piperidinyl)-4-(4-fluorophenyl)-5-[2-(2-methyl-4-fluorophenyl)-amino]pyrimidin-4-yl]imidazole;
1-Cyclohexyl-4-(4-fluorophenyl)-5-[[2-[N-(3-pyridyl)methyl]amino]pyrimidin-4-yl]imidazole;
1-(4-Piperidinyl)-4-(4-fluorophenyl)-5-[2-(2-methyl-5-fluorophenyl)amino]pyrimidin-4-yl]imidazole;
1-Isopropyl-4-(4-fluorophenyl)-5-[2-phenylamino-pyrimidin-4-yl]imidazole; or a pharmaceutically acceptable salt thereof.

### Claim 8 (depends on 7)

A pharmaceutical composition comprising a compound, or pharmaceutically acceptable salt thereof, according to claim 7, and a pharmaceutically acceptable carrier or diluent.

### Claim 9 (depends on 7)

A method of treating a CSBP/RK/p38 kinase mediated disease in a mammal in need thereof, which comprises administering to said mammal an effective amount of a compound according to claim 7.

### Claim 10 (depends on 9)

The method according to claim 9 wherein the CSBP/RK/p38 kinase mediated disease is selected from psoriatic arthritis, Reiter's syndrome, rheumatoid arthritis, gout, traumatic arthritis, rubella arthritis and acute synovitis, rheumatoid spondylitis, osteoarthritis, gouty arthritis, sepsis, septic shock, endotoxic shock, gram negative sepsis, toxic shock syndrome, Alzheimer's disease, stroke, neurotrauma, CNS injury, restinosis, reperfusion injury, asthma, adult respiratory distress syndrome, cerebral malaria, chronic pulmonary inflammatory disease, silicosis, pulmonary sarcososis, bone resorption disease, osteoporosis, restenosis, cardiac and renal reperfusion injury, thrombosis, glomerularnephritis, diabetes, graft vs. host reaction, allograft rejection, inflammatory bowel disease, Crohn's disease, ulcerative colitis, multiple sclerosis, muscle degeneration, eczema, contact dermatitis, psoriasis, pyresis, sunburn, or conjunctivitis.

### Claim 11 (depends on 7)

A method of treating inflammation in a mammal in need thereof, which comprises administering to said mammal an effective amount of a compound according to claim 7.

### Claim 12 (depends on 7)

A method of treating osteoporosis in a mammal in need thereof, which comprises administering to said mammal an effective amount of a compound according to claim 7.

### Claim 13

A process for producing a compound of the formula:
wherein:
Cmpd. No. R2 Ra 1 cyclohexyl phenyl 2 cyclohexyl 3 cyclohexyl 4 cyclohexyl 5 cyclohexyl (3,3-diphenyl)propyl 6 cyclohexyl (1-methyl-3-phenyl)propyl 7 (3-trifluoromethyl)phenyl 8 (3,4-dimethoxybenzamide ethyl 3,4-dichlorobenzyl 9 ethoxyacetamide-ethyl 4-methoxybenzyl 10 isopropyl phenyl 11 cyclopentyl phenyl 12 (1-t-butoxycarbonyl)-4-piperidinyl (2-methyl-4-fluorophenyl) 13 4-piperidinyl (2-methyl-4-fluorophenyl) 14 4-pipendinyl (2-methyl-5-fluorophenyl) 15 4-piperidinyl (2,6-dimethylphenyl) 16 4-piperidinyl (2-methylphenyl) 17 4-fluorophenyl phenyl 18 4-fluorophenyl (2-methylphenyl) 19 4-fluorophenyl (2,6-dimethylphenyl) 20 4-fluorophenyl *denoting point of attachment; which process comprises reacting a compound of the formula: with a compound of the formula:
wherein R is a substituted or unsubstituted C 1-4 alkyl; Ar is an unsubstituted or substituted aryl; R2 is as defined above, and p is =2; to yield a compound of the formula:
wherein R and R2 are as defined above; and using oxidizing conditions to make the corresponding sulfone or sulfoxide derivative; and using displacement conditions reacting the corresponding sulfone or sulfoxide derivative with the desired NH2Ra moiety, or a metal precursor thereof, to yield a compound as defined in the table above.

### Claim 14 (depends on 13)

The process according to claim 13 wherein the NH2Ra moiety is activated by trimethyl aluminium to yield the aluminum salt precurser; or NH2Ra is activated by butyl lithium to yield the lithium salt precursor.

### Claim 15

The compound 1-(4-Piperidinyl)-4-(4-fluorophenyl)-5-[2-(2-methylphenyl)amino]pyrimidin-4-yl]imidazole; or a pharmaceutically acceptable salt thereof.

### Claim 16

A pharmaceutical composition comprising 1-(4-Piperidinyl)-4-(4-fluorophenyl)-5-[2-(2-methylphenyl)amino]pyrimidin-4-yl]imidazole, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or diluent.

### Claim 17 (depends on 15)

A method of treating a CSBP/RK/p38 kinase mediated disease in a mammal in need thereof, which comprises a4administering to said mammal an effective amount of a compound according to claim 15.

### Claim 18 (depends on 17)

The method according to claim 17 wherein the CSBP/RK/p38 kinase mediated disease is selected from psoriatic arthritis, Reiter's syndrome, rheumatoid arthritis, gout, traumatic arthritis, rubella arthritis and acute synovitis, rheumatoid spondylitis, osteoarthritis, gouty arthritis, sepsis, septic shock, endotoxic shock, gram negative sepsis, toxic shock syndrome, Alzheimer's disease, stroke, neurotrauma, CNS injury, restinosis, reperfusion injury, asthma, adult respiratory distress syndrome, cerebral malaria, chronic pulmonary inflammatory disease, silicosis, pulmonary sarcososis, bone resorption disease, osteoporosis, restenosis, stroke, cardiac and renal reperfusion injury, chronic renal failure, congestive heart failure, angiogenic diseases, thrombosis, glomerularnephritis, diabetes, graft vs. host reaction, allograft rejection, inflammatory bowel disease, Crohn's disease, ulcerative colitis, multiple sclerosis, muscle degeneration, eczema, contact dermatitis, psoriasis, pyresis, sunburn, or conjunctivitis.

### Claim 19 (depends on 15)

A method of treating inflammation in a mammal in need thereof, which comprises administering to said mammal an effective amount of a compound according to claim 15.
